The Synergistic Effect of Valsartan and LAF237 [(S)‎-1-[(3-Hydroxy-1-Adamantyl)‎Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice

Abstract EN

Aim.

To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP-IV inhibitor) on prevention against oxidative stress and inflammation injury in db/db mice aorta.

Methods.

Db/db mice (n=40) were randomized to receive valsartan, LAF237, valsartan plus LAF237, or saline.

Oxidative stress and inflammatory reaction in diabetic mice aorta were examined.

Results.

Valsartan or LAF237 pretreatment significantly increased plasma GLP-1 expression, reduced apoptosis of endothelial cells isolated from diabetic mice aorta.

The expression of NAD(P)H oxidase subunits also significantly decreased resulting in decreased superoxide production and ICAM-1 (fold change: valsartan : 7.5 ± 0.7, P<0.05; LAF237: 10.2 ± 1.7, P<0.05), VCAM-1 (fold change: valsartan : 5.2 ± 1.2, P<0.05; LAF237: 4.8 ± 0.6, P<0.05), and MCP-1 (fold change: valsartan: 3.2 ± 0.6, LAF237: 4.7 ± 0.8; P<0.05) expression.

Moreover, the combination treatment with valsartan and LAF237 resulted in a more significant increase of GLP-1 expression.

The decrease of the vascular oxidative stress and inflammation reaction was also higher than monotherapy with valsartan or LAF237.

Conclusion.

These data indicated that combination treatment with LAF237 and valsartan acts in a synergistic manner on vascular oxidative stress and inflammation in type 2 diabetic mice.